• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SERTINDOLE Drug Record

  • Summary
  • Interactions
  • Claims
  • SERTINDOLE chembl:CHEMBL12713

    Alternate Names:

    SERTINDOLE
    LU-23-174
    LU 23-174
    SERLECT
    1-[2-[4-[5-CHLORO-1-(4-FLUOROPHENYL)-INDOL-3-YL]-1-PIPERIDYL]ETHYL]IMIDAZOLIDIN-2-ONE
    SERTINDOLUM
    SERTINDOL
    SERLECT®
    SERDOLECT®
    chembl:CHEMBL12713
    chemidplus:106516-24-9
    rxcui:41996
    drugbank:06144
    pubchem.compound:60149

    Drug Info:

    FDA Approval approved
    Drug Class small molecule
    Drug Indications antipsychotic agent
    Year of Approval not approved by the fda
    Drug Class antipsychotic agents
    (1 More Sources)

    Publications:

    Mørk et al., 2009, Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved., Psychopharmacology (Berl.)
    Cincotta et al., 2010, Emerging role of sertindole in the management of schizophrenia., Neuropsychiatr Dis Treat
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Lindström et al., 2006, Sertindole: efficacy and safety in schizophrenia., Expert Opin Pharmacother
    Seeman, 2008, Dopamine D2(High) receptors moderately elevated by sertindole., Synapse
    Rampe et al., 1998, The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG., J. Pharmacol. Exp. Ther.
    Kang et al., 2001, The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel., Biochem. Biophys. Res. Commun.
    Tang et al., 2001, Development and evaluation of high throughput functional assay methods for HERG potassium channel., J Biomol Screen
    Roden DM, 2004, Drug-induced prolongation of the QT interval., N Engl J Med
    Katchman AN et al., 2006, Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs., J Pharmacol Exp Ther
    Aronov AM, 2005, Predictive in silico modeling for hERG channel blockers., Drug Discov Today
    Hietala et al., 2001, Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment., Psychopharmacology (Berl.)
    Schreiber et al., 1994, Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone., Eur. J. Pharmacol.
    Pouzet et al., 2002, Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia., Pharmacol. Biochem. Behav.
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
  • SERTINDOLE   HTR6

    Interaction Score: 2.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Serdolect
    Novel drug target Established target

    PMIDs:
    11888555 19506838


    Sources:
    TdgClinicalTrial TEND

  • SERTINDOLE   ADRA1D

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Serdolect
    Novel drug target Established target

    PMIDs:
    16925508


    Sources:
    TdgClinicalTrial TEND

  • SERTINDOLE   HTR2C

    Interaction Score: 0.45

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Serdolect

    PMIDs:
    11594443 16925508


    Sources:
    TdgClinicalTrial TEND

  • SERTINDOLE   ADRA1B

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Serdolect
    Novel drug target Established target

    PMIDs:
    16925508


    Sources:
    TdgClinicalTrial TEND

  • SERTINDOLE   HTR2A

    Interaction Score: 0.28

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Serdolect
    Novel drug target Established target

    PMIDs:
    11594443 7530204 16925508


    Sources:
    TdgClinicalTrial TEND

  • SERTINDOLE   ADRA1A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name Serdolect

    PMIDs:
    11594443 16925508


    Sources:
    TdgClinicalTrial TEND

  • SERTINDOLE   DRD2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Serdolect
    Novel drug target Established target

    PMIDs:
    19506838 20856607 11752352 16925508 18293356


    Sources:
    TdgClinicalTrial TEND

  • SERTINDOLE   KCNH2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Serdolect
    Novel drug target Established target

    PMIDs:
    9694935 11511086 11689132 14999113 16278312 15718164


    Sources:
    TdgClinicalTrial PharmGKB

  • SERTINDOLE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • SERTINDOLE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SERTINDOLE   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: SERTINDOLE

    • Version: 01-August-2011

    Alternate Names:
    SERTINDOLE Primary Drug Name

    Drug Info:
    Drug Class antipsychotic agents
    Year of Approval not approved by the fda

    Publications:

  • TdgClinicalTrial: SERTINDOLE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antipsychotic agent
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: sertindole

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Aronov AM, 2005, Predictive in silico modeling for hERG channel blockers., Drug Discov Today
    Katchman AN et al., 2006, Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs., J Pharmacol Exp Ther
    Roden DM, 2004, Drug-induced prolongation of the QT interval., N Engl J Med

  • DTC: SERTINDOLE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL12713 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL12713

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21